Nonimmunosuppressive Therapy Bests ARB for Cutting Proteinuira in IgA Nephropathy

(MedPage Today) -- AUSTIN, Texas -- Once-daily sparsentan (Filspari) was better at reducing proteinuria than standard treatment in IgA nephropathy, according to a prespecified interim analysis of the PROTECT trial. By week 36 of treatment in...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news